-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Pfizer's Income Statement
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue |
|
$81.29 B | $100.33 B | $59.55 B | $63.63 B | $62.58 B |
| Cost of Revenue |
|
$34.41 B | $38.24 B | $29.21 B | $21.78 B | $18.57 B |
| Gross Profit |
|
$46.88 B | $62.09 B | $30.34 B | $41.85 B | $44.01 B |
| Research & Development |
|
$13.83 B | $11.43 B | $10.58 B | $10.74 B | $11.98 B |
| Selling,General & Administrative |
|
$12.25 B | $13.12 B | $14.47 B | $14.63 B | $13.35 B |
| Operating Expense |
|
$26.08 B | $24.54 B | $25.05 B | $25.36 B | $28.58 B |
| Operating Income |
|
$20.79 B | $37.55 B | $5.29 B | $16.48 B | $15.44 B |
| Net Income |
|
$22.15 B | $31.37 B | $2.13 B | $8.02 B | $7.77 B |
Pfizer's Balance Sheet
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$31.07 B | $22.73 B | $12.69 B | $20.48 B | - |
| Inventories |
|
$9.06 B | $8.98 B | $10.19 B | $10.85 B | - |
| Total Current Assets |
|
$59.69 B | $51.26 B | $43.33 B | $50.36 B | - |
| Property,Plant and Equipment |
|
$14.88 B | $16.27 B | $18.94 B | $18.39 B | - |
| Goodwill |
|
$49.21 B | $51.38 B | $67.78 B | $68.53 B | - |
| Total Assets |
|
$181.48 B | $197.21 B | $226.50 B | $213.40 B | - |
| Total Liabilities |
|
$104.01 B | $101.29 B | $137.21 B | $124.90 B | -$93.10 B |
| Retained Earnings |
|
$103.39 B | $125.66 B | $118.35 B | $116.73 B | - |
| Total Shareholder Equity |
|
$77.20 B | $95.66 B | $89.01 B | $88.20 B | $93.10 B |
| Common Stock |
|
$473.00 M | $476.00 M | $478.00 M | $480.00 M | - |
Pfizer's Cash flow
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$5.19 B | $5.06 B | $6.29 B | $7.01 B | - |
| Dividends Payout |
|
-$8.73 B | -$8.98 B | -$9.25 B | -$9.51 B | - |
| Capital Expenditures (Capex) |
|
-$2.71 B | -$3.24 B | -$3.91 B | -$2.91 B | - |
| Free Cash Flow (FCF) |
|
$29.87 B | $26.03 B | $4.79 B | $9.84 B | - |
Pfizer's Profitability
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Gross Profit |
|
$46.88 B | $62.09 B | $30.34 B | $41.85 B | $44.01 B |
| Gross Profit Margin (%) |
|
57.67% | 61.89% | 50.95% | 65.77% | 70.33% |
| Operating Income |
|
$20.79 B | $37.55 B | $5.29 B | $16.48 B | $15.44 B |
| Operating Income Margin (%) |
|
25.58% | 37.43% | 8.89% | 25.91% | 24.67% |
| Net Income |
|
$22.15 B | $31.37 B | $2.13 B | $8.02 B | $7.77 B |
| Net Income Margin (%) |
|
27.25% | 31.26% | 3.58% | 12.60% | 12.42% |
| EBITDA |
|
$30.79 B | $41.03 B | $9.56 B | $18.13 B | $15.10 B |
| EBITDA Margin (%) |
|
37.88% | 40.90% | 16.05% | 28.49% | 24.12% |
Pfizer's Ratios
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
28.69% | 32.79% | 2.40% | 9.09% | 8.35% |
| Return on Assets (ROA) |
|
12.20% | 15.90% | 0.94% | 3.76% | - |
| Debt to Equity |
|
47.92% | 36.44% | 79.59% | 75.95% | 69.60% |
| Debt to total asset |
|
20.39% | 17.68% | 31.28% | 31.39% | 31.13% |
| Enterprise value to revenue |
|
4.50 | 3.21 | 3.87 | 3.35 | 2.26 |
| Enterprise value to EBITDA |
|
11.88 | 7.84 | 24.11 | 11.74 | 9.37 |
| Enterprise value |
|
$365.79 B | $321.80 B | $230.45 B | $212.87 B | $141.50 B |
| Tax Rate (%) |
|
7.62% | 9.58% | -105.29% | -0.35% | -3.54% |
Frequently Asked Questions
